agenda
COVERING ALL THE IMPORTANT TOPICS
Amsterdam, 12 - 13 March 2024
Schedule
Create your personal agenda –check the favourite icon
Mar 128:55
Conference pass
Chair's remarks
Keynotes
Chris Mancill, Senior Vice President, Head, Global Market Access, Pricing, and Value Demonstration, Bristol Myers Squibb
Mar 129:00
Conference pass
Keynote presentation
Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, Janssen
Mar 1210:20
Conference pass
Overcoming the access barrier: inclusive growth around the globe
Keynotes
Mar 1211:40
Conference pass
Chair's Remarks
Evidence
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Mar 1211:40
Conference pass
Chair's Remarks
Market Access
Laurene Redding, Global Head, Value, Access & Pricing, ex-China, Beigene
Mar 1211:40
Conference pass
Chair's Remarks
Pricing
Astrid Buys, Director, Global Head of Tenders and Pricing, Bavarian Nordic A/S
Mar 1211:40
Conference pass
Chair's Remarks
Rare Diseases
Gina Ewy, VP, Head of Global Market Access, Hansa Biopharma
Mar 1211:40
Conference pass
Chair's Remarks
Advanced Therapies
Fabrizio Gianfrate, Full Professor, Health Economics and Outcomes Research, Former AIFA
Mar 1211:40
Conference pass
Chair's Remarks
Digital Transformation
Ivanna Rosendal, Senior Director, Head of Commercial and Medical IT, Ascendis Pharma A/S
Mar 1211:40
Conference pass
Chair's Remarks
HTA
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 1211:40
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Shrividya Iyer, Independent Expert, RWE and HEOR, Independent Expert
Mar 1211:45
Conference pass
Patient centred integrated evidence generation
Evidence
Agathe Le Lay, Vice President, Head of Global Value Evidence & Patient Insights, Medical Affairs, H. Lundbeck A/S
Mar 1211:45
Conference pass
European pricing and developments: future out-looks & rare diseases
Pricing
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Mar 1211:45
Conference pass
Evidence generation in rare disease development programs
Rare Diseases
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Mar 1211:45
Conference pass
Early pipeline development for advanced therapies
Advanced Therapies
Kalitsa Filioussi, Global Director, Early Access, Novartis
Mar 1211:45
Conference pass
HTA for artificial intelligence: where are we now?
Digital Transformation
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Mar 1211:45
Conference pass
Minding the evidence gap: a day in a life of a HTA assessor
HTA
Zinajda Zolic-Karlsson, Senior advisor HTA, Norwegian Medicines Agency
Mar 1211:45
Conference pass
Clinical outcomes assessments in rare diseases and HEOR
Health Economics & Outcomes Research
Dilesh Doshi, Vice President, Global Health Economics and Outcomes Research, Acadia Pharmaceuticals Inc.
Mar 1212:25
Conference pass
Evidence for HTA: delivering the biggest impact
Evidence
Sandeep Kiri, Global Head, Health Economics and HTA Evidence, UCB
Mar 1212:25
Conference pass
Opportunities and challenges in the evolving healthcare procurement environment
Market Access
Donal O'Sullivan, Vice President, Head of Pricing & Tenders, CSL Vifor
Mar 1212:25
Conference pass
Opportunities and challenges in the evolving healthcare procurement environment
Pricing
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Mar 1212:25
Conference pass
Driving solutions and understanding barriers for patient access in rare diseases
Rare Diseases
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
Mar 1212:25
Conference pass
Patient access for advanced therapies
Advanced Therapies
Rita Shorjian, Commercial Director, Determatology, Intercontinental, Middle East, Africa and Russia, Abbvie
Mar 1212:25
Conference pass
Improving access to digital therapeutics in Europe
Digital Transformation
Tina Taube, Director, Market Access and Orphan Drug Policy Lead, EFPIA
Mar 1212:25
Conference pass
Framework and implementation for HTAR regulation
HTA
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Mar 1212:25
Conference pass
Innovating economic processes for improved patient access
Health Economics & Outcomes Research
Ariella Toren, Director, Medicine and Medical Technologies, HMOS Department, Ministry of Health, Israel
Mar 1212:45
Conference pass
Healthcare digital transformation towards profitable growth
Digital Transformation
Mar 1214:05
Conference pass
01 Evidence Panel – Current HTA trends and impacts on evidence
Evidence
Daniel Jackson, Global Head, Market Access Policy, UCB
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Tanja Podkonjak, Director, Access and Reimbursement Policy, Oncology, EUCAN, Takeda
Diana Sinkevich, Head of Access, Chiesi
Shuvayu Sen, Vice President and Head of Oncology, Center of Observational & Real World Evidence, Merck
Enkeleida Nikai-Fitzgerald, Vice President, Head of Global Real-World Evidence, GenMed, SANOFI
Mar 1214:05
Conference pass
02 Market Access Panel – Title TBC
Market Access
Matt Cullen, Vice President, Value, Access & Policy, Lexicon Pharmaceuticals, Inc.
Julien Patris, Head of Patient Advocacy and Public Policy, EMEA, arGEN-X
Birgit Holz, Global Head, Contracting Innovation, Sanofi
Mata Charokopou, Senior Director, Global Head of Access, Pricing & Value, UCB
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Pernille Storm, Vice President, Global Pricing and Market Access, Lundbeck
Mar 1214:05
Conference pass
04 Rare Diseases – Barriers and solutions to medicine access for patients with rare diseases
Rare Diseases
Christine Mossa, Senior Director, Regulatory Affairs, Public Affairs, Value & Access, Ipsen Biopharmaceuticals Canada Inc.
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Juliette Vila Sinclair/Spence, Rare Disease Patient Advocate & Chairwoman, Acanthamoeba Keratitis Eye Foundation
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
lorenzo capretto, Market Access Lead EU&EM, Global Rare Disease, Chiesi Farmaceutici SpA
Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Diseases & Rare Diseases International
Mar 1214:05
Conference pass
06 Evidence Panel - Efficiency in evidence generation for decision making readiness
Digital Transformation
Gorana Capkun-Niggli, Executive Director, Global Health, Real World Evidence Enablement, Novartis
Nadia Kaskure, Strategy Partner, Porfolio Strategy, Access and Pricing, Novo Nordisk
Melvin Olson, Executive Director, Head of Integrated Evidence Strategy and Innovation, Novartis
Mar 1214:05
Conference pass
08 Market Access Panel – Market access for advanced diagnostics and comprehensive genomic profiling
Health Economics & Outcomes Research
Benjamin Gannon, Vice President, International, Guardant Health
Mar 1215:10
Conference pass
Chair's Remarks
Market Access
Michael Mueller, Head Of Market Access, Western Europe, Sun pharma
Mar 1215:10
Conference pass
Chair's Remarks
Pricing
Tomaso Piaggio, Director, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Mar 1215:10
Conference pass
Chair's Remarks
Rare Diseases
Luigi Angelillo, Director, Market Access EMEA, Argenx
Mar 1215:10
Conference pass
Chair's Remarks
Advanced Therapies
Lisette Kaskens, Director, Market Access, Europe, LATAM & Canada, Ferring Pharmaceuticals
Mar 1215:10
Conference pass
Chair's Remarks
Digital Transformation
Igor Solev, Global Head of Market Access, Policy & External Payer Affairs, Abbott Laboratories
Mar 1215:10
Conference pass
Chair's Remarks
HTA
Josep Maria Guiu Segura, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Mar 1215:10
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Rhys Williams, Vice President, Evidence Generation Strategy and Health Economics, Global Medical Affairs (ex-China), Beigene
Mar 1215:15
Conference pass
Are we ready to reach the WHO’s goals for oncology?
Evidence
Rafael Souza, Director, Access Solutions & Pricing, New Markets, Beigene
Mar 1215:15
Conference pass
Bridging early access schemes during negotiations
Market Access
Ad Antonisse, Director, Market Access & External Affairs, Astrazeneca
Mar 1215:15
Conference pass
Pricing updates for Spain: future challenges
Pricing
José Luis Sánchez Chorro, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Mar 1215:15
Conference pass
The patient journey of accessing new treatments
Rare Diseases
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Mar 1215:15
Conference pass
Pricing approaches for gene therapies: future innovations
Advanced Therapies
Lara Pippo, Head Of Market Access & Government Affairs, Italy, CSL Behring
Mar 1215:15
Conference pass
How pharma can utilize patient level data for integrated business analytics
Digital Transformation
Teddy Sun, Evidence Generation Lead, Nordic Data Digital & Technology (DDT), Takeda
Mar 1215:15
Conference pass
Cost effectiveness thresholds and healthcare decision making: challenges for HTAs
HTA
Hans Severens, Independent HTA Expert, Former Vice President,, Dutch Health Council
Mar 1215:15
Conference pass
Outcomes research and real-world evidence for women’s health
Health Economics & Outcomes Research
Katja Lundell, Senior Director, Global Head of Pricing, Access and Communications, theramex
Mar 1215:35
Conference pass
Silver sponsor presentation - LCP
Market Access
Ad Antonisse, Director, Market Access & External Affairs, Astrazeneca
Mar 1215:55
Conference pass
Integrated evidence approaches: opportunities and challenges
Evidence
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Mar 1215:55
Conference pass
Driving solutions and understanding barriers for ac-cess to molecular diagnostics in LMICs
Market Access
Francesco Marinucci, Director, Global Market Access, Abbott
Mar 1215:55
Conference pass
Value based pricing for off-patent pharmaceuticals
Pricing
Kalman Emry Wijaya, Director, Head of Pricing, Tender and Contracting, Biogen
Mar 1215:55
Conference pass
Navigating implications of new legislation for orphan medicines: how patient voices can contribute
Rare Diseases
Helen Stoop, Senior Director, Head of Patient Advocacy, Europe & Canada, Takeda
Mar 1215:55
Conference pass
Managed entry agreements and solutions for access challenges in rare diseases and advanced therapies
Advanced Therapies
Charles Brown, Director, Global Pricing & Contracting, Novartis
Mar 1215:55
Conference pass
The HMOs in the era of drug competition: creating innovative solutions
Digital Transformation
Michal Davidescu, Health Access Specialist, Pfizer
Mar 1215:55
Conference pass
Impacts of EU HTA regulation on the German AMNOG
HTA
Friedhelm Leverkus, Director, HTA & Outcomes Research, Pfizer
Mar 1215:55
Conference pass
Modelling health inequalities in HEOR
Health Economics & Outcomes Research
Diar Fattah, Director, Health Economics and Outcomes Research, Vertex Pharmaceuticals
Mar 1216:45
Conference pass
Chair's Remarks
Evidence
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Mar 1216:45
Conference pass
Chair's Remarks
Market Access
Marie-Sharmila Blandino, Director, Global Access Strategy Lead, Amgen
Mar 1216:45
Conference pass
Chair's Remarks
Pricing
Penny Lovell, Head of Access, Pricing and External Engagement, UCB
Mar 1216:45
Conference pass
Chair's Remarks
Rare Diseases
Thomas Hasmann, Head of Market Access, Europe, KalVista Pharmaceuticals
Mar 1216:45
Conference pass
Chair's Remarks
Advanced Therapies
Lorenzo Mantovani, Professor of Public Health, University Of Milano - Bicocca
Mar 1216:45
Conference pass
Chair's Remarks
HTA
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, National Evaluation Committee for Specialised Medicine, CZ
Mar 1216:45
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Ana Filipa Alexandre, Vice President, Head of Pricing and Market Access, Santen
Mar 1216:50
Conference pass
Balancing trade-offs to ensure broad patient access in infectious diseases
Evidence
Elizabeth Kinter, Vice President, Head of Evidence, Value and Access, Vir Biotechnology
Mar 1216:50
Conference pass
Novel payment models in oncology
Market Access
Alison Horsfield, Director, Global Access Strategy, AstraZeneca
Mar 1216:50
Conference pass
Pricing implications in the US on small biotechs: managing gross to net
Pricing
Jake McDowell, Vice President, Head of Market Access and Pricing, Partner Therapeutics
Mar 1216:50
Conference pass
Launching products for rare diseases: adjusting to international and local hurdles
Rare Diseases
Fabian Schmidt, Head of Market Access / HEOR, Recordati Rare Diseases Sarl
Mar 1216:50
Conference pass
Ensuring that academic innovations in advanced therapies reach patients
Advanced Therapies
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mar 1216:50
Conference pass
Use of data for HTA: NICE’s digital journey
Digital Transformation
Shaun Rowark, Associate Director, Data Access and Analysis, NICE
Mar 1216:50
Conference pass
NHS and NICE processes for diagnostics
HTA
Shabana Malik, Director, Access, UK & Ireland, BIOMERIEUX
Mar 1216:50
Conference pass
Modelling novel and societal value elements for holistic value assessment in HTA
Health Economics & Outcomes Research
Ramiro Gilardino, Senior Director, Global HTA & Access Policy Lead, MSD
Mar 1217:30
Conference pass
Using real world evidence for support patient access
Evidence
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Mar 1217:30
Conference pass
Access to medicines in LMICs
Market Access
Annie Syntosi, Global Associate Director, Value & Access, HEOR, Global Health,, Novartis Pharma AG
Mar 1217:30
Conference pass
Finding common ground: collaborating between patients, payers and industry
Pricing
Nidhi Dani, Director, Global Market Access, Novartis
Mar 1217:30
Conference pass
Conditional reimbursement policies: moving forward with uncertain evidence
Rare Diseases
Paul Slobbe, Director, Access and External Affairs, Takeda Nederland B.V.
Mar 1217:30
Conference pass
What have we learned and the future outlook for risk sharing agreements for ATMPs
Advanced Therapies
Farzana Malik, Transmineo
Mar 1217:30
Conference pass
Digital disruption demystified: practical approached to digital transformation in access
Digital Transformation
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Mar 1217:30
Conference pass
Implementing risk sharing agreements
HTA
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Mar 1217:30
Conference pass
Innovation in anti-infectives valuations
Health Economics & Outcomes Research
Amer Al-Taie, Senior Director, Value & Evidence Team Lead, Pfizer
Create your personal agenda –check the favourite icon
Mar 138:55
Conference pass
Chair's Remarks
Keynotes
Marco Rauland, Vice President, Global Head of GVAP Strategic Planning & Data Science, Global Evidence Demonstration, Market Access and Pricing, Merck Group
Mar 139:00
Conference pass
Keynote presentation
Keynotes
Charles Makin, Global Head, Health Economics and Outcomes Research, HTA & Real-World Evidence, Biogen
Mar 139:20
Conference pass
Trends for affordable access: reducing disparities in global inequity
Keynotes
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Mar 1310:00
Conference pass
Panel discussion – Ways that AI can transform pharma market access
Keynotes
Marco Rauland, Vice President, Global Head of GVAP Strategic Planning & Data Science, Global Evidence Demonstration, Market Access and Pricing, Merck Group
Alexander Bastian, Vice President, Value & Market Access, A.M. Pharma
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Chris Mancill, Senior Vice President, Head, Global Market Access, Pricing, and Value Demonstration, Bristol Myers Squibb
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
Rogerio Ribeiro, Senior Vice President, Head of Global Commercial, Vaccines Business Unit, Takeda
Mar 1311:40
Conference pass
Chair's Remarks
Evidence
Jonathan Plumb, Vice President, Head, Global Value & Access, Ferring Pharmaceuticals SA
Mar 1311:40
Conference pass
Chair's Remarks
Market Access
Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Mar 1311:40
Conference pass
Chair's Remarks
Pricing
Eduardo Santos, Executive Director, Therapeutic Area Head, General Medicines, Global Value, Access & Pricing, Amgen
Mar 1311:40
Conference pass
Chair's Remarks
Rare Diseases
Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
Mar 1311:40
Conference pass
Chair's Remarks
Advanced Therapies
Ishita Gaikwad, Director, Global Integrated Access Strategy, Amgen
Mar 1311:40
Conference pass
Chair's Remarks
Digital Transformation
Johnny Bane, Head of Market Access, Accord Healthcare
Mar 1311:40
Conference pass
Chair's Remarks
HTA
Alina Charter, VP Market Access, Pricing and Policy, Alnylam
Mar 1311:40
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Riad Dirani, Vice President, Global HEOR, Medical Operations & Excellence, Teva Pharmaceuticals
Mar 1311:45
Conference pass
Evidence generation for innovative therapies in mental health
Evidence
Lucinda Orsini, Vice President, Value and Outcomes Research, COMPASS Pathways
Mar 1311:45
Conference pass
Investment strategies in market access viability: policies in reimbursement
Market Access
Erin Mistry, Executive Vice President, Chief Commercial Officer, CorMedix Inc
Mar 1311:45
Conference pass
Value based healthcare: what’s next for the innovative value space?
Pricing
Chris Bidad, Global Head, Access Strategy and Payer Policy, AstraZeneca
Mar 1311:45
Conference pass
Delivering on value-based therapies for rare diseases in Canada
Rare Diseases
Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Diseases & Rare Diseases International
Mar 1311:45
Conference pass
Gaining a commercial presence in Europe with advanced diagnostics
Advanced Therapies
Benjamin Eckert, Senior Vice President, Market Access, Adaptive Biotechnologies
Mar 1311:45
Conference pass
Data assets and AI platforms: multi-modal approaches across the evidence spectrum
Digital Transformation
Sean McElligott, Executive Director, Head, US Health Economics Outcomes Research, Novartis
Mar 1311:45
Conference pass
Value proposition of innovations: complexities for HTAs
HTA
Michele de Guise, President and Chief Executive Officer, INESSS
Mar 1311:45
Conference pass
HEOR and access strategy: changing environments and broadening the definition of value
Health Economics & Outcomes Research
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 1312:25
Conference pass
Evidence generation for policy development: alleviating health disparities
Evidence
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Janssen
Mar 1312:25
Conference pass
Innovative medicines platform: what does this mean for EU access policy?
Market Access
Matt Slabbert, Vice President, Global Head of Pharma Public Affairs, Bayer
Mar 1312:25
Conference pass
Pricing from a start-up perspective
Pricing
Keith White, Head, Global Market Access, Amylyx Pharmaceuticals
Mar 1312:25
Conference pass
Engagements with payers for a product in an ultra-rare disease
Rare Diseases
Luca Tofani, Director, Pricing and Reimbursement, S.I.F.I. Spa
Mar 1312:25
Conference pass
Transition of a hospital set ATMP into an outpatient setting
Advanced Therapies
Andre Roeder, Head, Global Market Access, TETEC AG
Mar 1312:25
Conference pass
Supporting the NHS in digital transformation: partnerships for innovation
Digital Transformation
Sarah Ferry, Senior Policy Advisor, Innovation & Life Sciences, NHS Confederation
Mar 1312:25
Conference pass
Equity of access: developing ethical standards
HTA
Lorenzo Montrasio, Senior Scientific Officer, Council of Europe
Mar 1312:25
Conference pass
When is the ideal moment to start your HEOR activities within product development?
Health Economics & Outcomes Research
Kun Shi-van Wielink, EMEA Associate Director, HEOR/RWE Market Access, Santen
Mar 1312:45
Conference pass
Strategic gross to net best practices in healthcare
Pricing
Mar 1314:05
Conference pass
01 Evidence Panel – Designing clinical development programmes: optimizing evidence generation for market access
Evidence
Steve Sandor, Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals , Inc.
Adrian Harrington, Senior Director, Value & Access, Biogen
Elisa Crovato, Director, Pricing & Market Access, Chiesi Group
Lara J. Wolfson, Associate Vice President, Head of HTA Statistics, MSD
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 1314:05
Conference pass
03 Pricing Panel – Tiered pricing for varied markets: is it of value to patient access?
Pricing
Seema Sondhi, Vice President, Head of Global Strategic Projects, Takeda
Alexander Roediger, Associate Vice President, Global Lead, Oncology Policy, MSD
Nick Besseling, Manager, Value Strategies & Agreements, Astrazeneca
Bart Van Den Daele, Director, Market Access, Head of External Affairs, GILEAD SCIENCES
Dierk Neugebauer, Vice President, Market Access, Bristol Myers Squibb
Peter Sajosi, Director, Regional Value and Access Lead, Amgen
Mar 1314:05
Conference pass
04 Rare Diseases – Playing nicely in the same sandbox: working together for patient access
Rare Diseases
Dawn Ireland, President & Founder, CDH International
Tal Morginstin, Director, HTA division, Ministry of Health, Israel
Josie Godfrey, Co-Chief Executive Officer, Realise Advocacy
Diego Ardigò, Global Rare Disease, Research & Development Head & Executive Board Member and Vice Chair, Chiesi Group & EUCOPE
Kim Stephens, Executive Director, Muenzer MPS Research & Treatment Center
Luca Luigi Polastri, Global Director, Payor Value and Patient Access Head, Kyowa Kirin
Mary Lynne Van Poelgeest-Pomfret, President, World Federation for Incontinence and Pelvic Problems (WFIPP)
Mar 1314:05
Conference pass
05 Advanced Therapies Panel – Access to gene therapies: challenges, opportunities and learnings
Advanced Therapies
Gunter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, novartis gene therapies
Sheena Thakkar, Director, Value & Evidence, Pfizer
Andrew Olaye, Executive Director, Head of Market Access and Partnership EMEA, Orchard Therapeutics Ltd
Mar 1314:05
Conference pass
06 Digital Transformation Panel – Empowering patients to collect their outcomes: making value-based healthcare a reality
Digital Transformation
Hélène Karcher, Global Head, Real World Evidence, Ophthalmology, Respiratory and Allergy, Novartis
Jennifer Quinn, Head of Global Value and Access, Debiopharm International
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Mar 1314:05
Conference pass
07 HTA Panel - Stakeholders' views on the implementation of the EU Health Technology Assessment (HTA)
HTA
Thomas Grub, Senior Expert, Global Pricing and Market Access, medac GmbH
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Ingrid Bettum, Senior Advisor, Norwegian Medicines Agency
Diogo Teixeira Pereira, Affiliate Member of NOVA SBE, Health Economics & Management Knowledge Center, Universidade NOVA de Lisboa
Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boehringer-Ingelheim
Mar 1314:05
Conference pass
08 Health Economics & Outcomes Research Panel - Title TBC
Health Economics & Outcomes Research
Ayman Semaan, Market Access & Pricing Lead, Biologix
Michael Schlander, Head of Division of Health Economics & Professor of Health Economics, German Cancer Research Center & University of Heidelberg
Marlene Gyldmark, Vice President, Global Head, HEOR & Epidemiology, Idorsia Pharmaceuticals
Matthias Bischof, Senior Director, Global Health Economics, Novartis Gene Therapies
Mar 1315:10
Conference pass
Chair's Remarks
Evidence
Kaan Tunceli, Vice President and Head, Global Value and Real World Evidence, Otsuka Pharmaceutical
Mar 1315:10
Conference pass
Chair's Remarks
Market Access
Allister Upton, Director, Market Access and Business Development, EMEA, Alimera Sciences Ltd
Mar 1315:10
Conference pass
Chair's Remarks
Pricing
Sebastian Kessel, Senior Director, Head of Market Access & External Engagement Germany, UCB
Mar 1315:10
Conference pass
Chair's Remarks
Rare Diseases
Marcus Dahlman, Head of Market Access Europe, Hansa Biopharma
Mar 1315:10
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Carme Pinyol, Early Products and HEOR Lead, Novartis
Mar 1315:15
Conference pass
Generating evidence for launches: creating innovative approaches
Evidence
Rachel Studer, Global Executive Director Launch Evidence, Novartis
Mar 1315:15
Conference pass
Reimbursement and pricing impacts on products in Israel
Market Access
Tomer Ben Zaken, Head of Commercial Operations & Trade, Astellas
Mar 1315:15
Conference pass
Pricing challenges for plasma derived therapies (PDTs): value-based pricing and procurement practices
Pricing
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Mar 1315:15
Conference pass
Market access with patient advocacy organisations: best practices and challenges
Rare Diseases
Kirsty Hoyle, Chief Executive Officer, Metabolic Support UK
Mar 1315:15
Conference pass
Defining value in advanced therapies: the case of hemophilia
Advanced Therapies
Paolo Angelo Cortesi, Assistant Professor in Public Health, Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
Mar 1315:15
Conference pass
Transforming discussions into understanding
Digital Transformation
Par Bolina, Adjunct Associate Professor, Medicinal Chemistry, Rutgers University
Mar 1315:15
Conference pass
Bridging of evidence to appraisals: aligning policy decisions
HTA
Goedele van Haasteren, Deputy chief Section HTA, Federal Office of Public Health, Switzerland
Mar 1315:15
Conference pass
The impact of austerity on healthcare: is cost containment the way forward?
Health Economics & Outcomes Research
Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Janssen
Mar 1315:55
Conference pass
Fit for purpose evidence generation to advance mental health
Evidence
Marianne Laouri, Executive Director, Value Demonstration, Specialty Products & Quality of Care, Boehringer Ingelheim
Mar 1315:55
Conference pass
Market access for digital health assets: creating frameworks for digital health technologies
Market Access
Bogdan Muresan, Director, Global HEOR, Astellas Pharma
Mar 1315:55
Conference pass
Pricing and contracting: not one size fits all
Pricing
Claudia Neuber, Head of Global Pricing, Oncology, AstraZeneca
Mar 1315:55
Conference pass
Orphan medicines regulation review – where are we now?
Rare Diseases
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Mar 1315:55
Conference pass
Prelaunch build up in US and Eu-rope for pricing and reimbursement in advanced therapies
Advanced Therapies
Dilip Patel, VP Market Access, Autolus
Mar 1315:55
Conference pass
Emerging digital health access in Asia Pacific
Digital Transformation
Anh Bourcet, External Advisor, Market Access Lead, APACMed, Asia Pacific Medical Technology Association
Mar 1315:55
Conference pass
HTA and price negotiations – experiences and expectations for the future
HTA
Erik Sagdahl, Head of Procurement, Pharmaceutical Division, Sykehusinnkjop
Mar 1315:55
Conference pass
Exploring patient registries for access: managing market access with real world evidence
Health Economics & Outcomes Research
Patricia Dorling, Head, Global HEOR and Real World Evidence, Chiesi Group
Mar 1316:45
Conference pass
Chair's Remarks
Pricing
Marina Faiella, Director, Forecasting and Business Analytics, Beigene
Mar 1316:45
Conference pass
Chair's Remarks
Rare Diseases
Simon Shohet, Vice President, Market Access, International, Amicus Therapeutics
Mar 1316:50
Conference pass
Creating a tool to assess obesity’s impact on a patient’s daily life
Evidence
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Mar 1316:50
Conference pass
Broadening the definition of value: comprehensive stakeholder perspectives
Market Access
Lori Yin, Associate Director, Access Lead, Roche
Mar 1316:50
Conference pass
Recent developments in pricing and commercial access frameworks in England
Pricing
Rob Kettell, Director, Commercial Medicines Negotiation and Complex Transactions, NHS England
Mar 1316:50
Conference pass
Alternative pricing structures for orphan medical products
Rare Diseases
Matthew Hanchard, Research Associate, University of Sheffield
Mar 1316:50
Conference pass
Creating virtual clinics for long covid: lessons learned from innovative digital health
Digital Transformation
Daniella Rahamim-Cohen, Director, Community Medicine, Maccabi Healthcare Services
Mar 1316:50
Conference pass
How new access schemes including risk management can contribute to coverage decisions in Latin America
HTA
Andres Pichon Riviere, Executive Director, Health Technology Assessment And Economic Evaluations, I.E.C.S.
Mar 1316:50
Conference pass
Addressing health inequities: bridging the gap
Health Economics & Outcomes Research
Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, Beigene
Mar 1317:30
Conference pass
A network of secure data environments: enabling health technology assessments
Evidence
Rebecca Cosgriff, Head of Data for R&D, NHS England
Mar 1317:30
Conference pass
Deconstructing value based pricing: an economist’s perspective
Pricing
Jörg Mahlich, Market Access and Government Affairs Lead, Miltenyi
Mar 1317:30
Conference pass
Are we making an impact with real world evidence?
HTA
last published: 21/Nov/23 16:15 GMT
Get Involved
Sponsorship & Exhibition Sales
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
Conference Production
George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940
Marketing Opportunities
Diana Cobzac
diana.cobzac@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events